Auditory MMN EEG in TRD in Response to Ketamine
This observational trial (n=30) will investigate the neurocomputational model of ketamine treatment response predictions in treatment-resistant depression (TRD).
Details
The study applies a validated computational model of the auditory mismatch negativity (MMN) to predict treatment response to clinical ketamine infusions in patients with treatment-resistant depression.
Participants receiving standard-of-care IV ketamine (0.5 mg/kg over 40 minutes, twice weekly for two weeks) will have EEG MMN recordings fitted to neural and circuit models to identify computational markers that predict clinical and antisuicidal response.
If successful, model-derived parameters from noninvasive EEG could enable single-patient prognostic statements to guide clinical decision-making for ketamine treatment in TRD.